Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Henrik Kahr Mathiesen"'
Autor:
Morten Blinkenberg, Henrik Kahr Mathiesen, Stephan Bramow, Finn Sellebjerg, Tine Iskov Kopp, Georgi Sirakov, Melinda Magyari, Jakob Schäfer, Matthias Kant, Hanna Joensen, Viktoria Papp, Luigi Pontieri, Peter Vestergaard Rasmussen, Michael Broksgaard Jensen, Jonas M. Berg
Publikováno v:
Pontieri, L, Blinkenberg, M, Bramow, S, Papp, V, Rasmussen, P V, Kant, M, Schäfer, J, Mathiesen, H K, Jensen, M B, Sirakov, G, Berg, J M, Kopp, T I, Joensen, H, Sellebjerg, F & Magyari, M 2022, ' Ocrelizumab treatment in multiple sclerosis : A Danish population-based cohort study ', European Journal of Neurology, vol. 29, no. 2, pp. 496-504 . https://doi.org/10.1111/ene.15142
Background and purpose: Real-world evidence regarding the effectiveness and safety of ocrelizumab for the treatment of multiple sclerosis (MS) is limited. The aim was to evaluate the effectiveness and safety of ocrelizumab treatment for MS in a real-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d54325df97cab01d7755fc6eb81c1222
https://vbn.aau.dk/da/publications/b6e29c9e-cb39-4725-9354-ab2fcec210ad
https://vbn.aau.dk/da/publications/b6e29c9e-cb39-4725-9354-ab2fcec210ad
Autor:
Alexis Montcuquet, Henrik Kahr Mathiesen, Tomas Kalincik, Marc Girard, Karolina Hankiewicz, Marco Onofrj, Francois Grand Maison, Raed Alroughani, Mathilde Lefort, Olivier Gout, Jeannette Lechner-Scott, Marc Debouverie, Julie Prevost, Eva Havrdova, Olivier Casez, Per Soelberg Sørensen, Pierre Duquette, Jean Pelletier, Claudio Solaro, Alessandra Lugaresi, Francesco Patti, Emmanuelle Leray, Johanna Balslev Andersen, Bassem Yamout, Céline Labeyrie, Karen Schreiber, Eric Thouvenot, Nils Koch-Henriksen, Michael Broksgaard Jensen, Elisabeth Maillart, Chantal Nifle, Stephan Bramow, Pierre Clavelou, Bruno Stankoff, Olivier Heinzlef, Finn Sellebjerg, Abir Wahab, Mark Slee, Gilles Defer, Pierre Labauge, Melinda Magyari, Steve Vucic, Guillermo Izquierdo, Helmut Butzkueven, Peter Vestergaard Rasmussen, Bertrand Bourre, Maria Trojano, Franco Granella, Corinne Pottier, Jette L. Frederiksen, Olga Skibina, Recai Turkoglu, Ivania Patry, Pierre Grammond, Bart Van Wijmeersch, Eric Berger, Aurélie Ruet, Serkan Ozakbas, Jonathan Ciron, Tünde Csépány, Jean Philippe Camdessanche, Sandra Vukusic, Nicolas Maubeuge, David Laplaud, Cavit Boz, Christine Lebrun, Claudia C. Hilt Christensen, Patrizia Sola, Vahid Shaygannejad, Romain Casey, Murat Terzi, Philippe Cabre, Jérôme De Seze, Abdullatif Al-Khedr, Dana Horakova, Pamela A. McCombe, Daniele Spitaleri, Alexandre Prat, Gilles Edan, Hélène Zéphir, Aude Marousset, Sifat Sharmin, Diana Ferraro, Sara Eichau, Rana Karabudak, Thibault Moreau
Publikováno v:
Multiple Sclerosis and Related Disorders
Multiple Sclerosis and Related Disorders, Elsevier, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Andersen, J B, Sharmin, S, Lefort, M, Koch-Henriksen, N, Sellebjerg, F, Sørensen, P S, Hilt Christensen, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, B V, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Sèze, J D, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, D A, Butzkueven, H, Kalincik, T, Vukusic, S & Magyari, M 2021, ' The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies ', Multiple Sclerosis and Related Disorders, vol. 53, 103012 . https://doi.org/10.1016/j.msard.2021.103012
Multiple Sclerosis and Related Disorders, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Multiple Sclerosis and Related Disorders, Elsevier, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Andersen, J B, Sharmin, S, Lefort, M, Koch-Henriksen, N, Sellebjerg, F, Sørensen, P S, Hilt Christensen, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, B V, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Sèze, J D, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, D A, Butzkueven, H, Kalincik, T, Vukusic, S & Magyari, M 2021, ' The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies ', Multiple Sclerosis and Related Disorders, vol. 53, 103012 . https://doi.org/10.1016/j.msard.2021.103012
Multiple Sclerosis and Related Disorders, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Background: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2f97bab4b243371f958204f4a99d850
http://hdl.handle.net/1942/34842
http://hdl.handle.net/1942/34842
Autor:
Mark Slee, Guillermo Izquierdo, Per Soelberg Soerensen, Karen Schreiber, Alexandre Prat, Francois Grand'Maison, Maria Trojano, Franco Granella, Pierre Duquette, David Laplaud, Elisabeth Maillart, Henrik Kahr Mathiesen, Bassem Yamout, Cavit Boz, Jean Pelletier, Corinne Pottier, Jette L. Frederiksen, Claudia Christina Pfleger, Tomas Kalincik, Olivier Gout, Daniele Spitaleri, Marc Girard, Marco Onofrj, Jérôme De Seze, Helmut Butzkueven, Emmanuelle Leray, Philippe Cabre, Julie Prevost, Abullatif Al-Khedr, Aude Maurousset, Eric Berger, Sifat Sharmin, Ivania Patry, Pamela A. McCombe, Patrizia Sola, Olga Skibina, Diana Ferraro, Pierre Clavelou, Francesco Patti, Finn Sellebjerg, Niels Koch-Henriksen, Alexis Montcuquet, Recai Turkoglu, Romain Casey, Bart Van Wijmeersch, Hélène Zéphir, Pierre Grammond, Dana Horakova, Davide Maimone, Serkan Ozakbas, Céline Labeyrie, Murat Terzi, Aurélie Ruet, Steve Vucic, Jonathan Ciron, Tünde Csépány, Nicolas Maubeuge, Bruno Stankoff, Mathilde Lefort, Katherine Buzzard, Karolina Hankiewicz, Jean-Philippe Camdessanché, Raed Alroughani, Michael Broksgaard Jensen, Pierre Labauge, Olivier Casez, Peter Vestergaard Rasmussen, Bertrand Bourre, Olivier Heinzlef, Gilles Defer, Gilles Edan, Alessandra Lugaresi, Abir Wahab, Melinda Magyari, Anneke van der Walt, Eva Havrdova, Johanna Balslev Andersen, Chantal Nifle, Stephan Bramow, Marc Debouverie, Thibault Moreau, Sandra Vukusic, Christine Lebrun-Frenay, Jeannette Lechner-Scott, Eric Thouvenot
Publikováno v:
CNS Drugs
CNS Drugs, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
Sharmin, S, Lefort, M, Andersen, J B, Leray, E, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand’Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frénay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Laplaud, D, Koch-Henriksen, N, Sellebjerg, F T, Soerensen, P S, Pfleger, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Magyari, M, Vukusic, S, Butzkueven, H, Kalincik, T & Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
CNS Drugs, Springer Verlag, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
CNS Drugs, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
Sharmin, S, Lefort, M, Andersen, J B, Leray, E, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand’Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frénay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Laplaud, D, Koch-Henriksen, N, Sellebjerg, F T, Soerensen, P S, Pfleger, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Magyari, M, Vukusic, S, Butzkueven, H, Kalincik, T & Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
CNS Drugs, Springer Verlag, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
Introduction: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. Objective:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db23efcded486e57c8c7b3dd1b8db8cf
http://hdl.handle.net/11585/853457
http://hdl.handle.net/11585/853457
Autor:
Henrik Kahr Mathiesen, Xingchen Wu, Lars G. Hanson, Morten Blinkenberg, Per Soelberg Sørensen, Arnold Skimminge, Olaf B. Paulson
Publikováno v:
Neurological Research. 36:701-708
To evaluate the prognostic value of the cortical N-acetyl aspartate to creatine ratio (NAA/Cr) in early relapsing-remitting multiple sclerosis (RRMS).Sixteen patients with newly diagnosed RRMS were studied by serial MRI and MR spectroscopic imaging (
Autor:
Morten Blinkenberg, T Tscherning, Per Soelberg Sørensen, Olaf B. Paulson, Agnete Jønsson, Claus Svarer, Søren Holm, Finn Sellebjerg, Lars G. Hanson, Henrik Kahr Mathiesen
Publikováno v:
Neurological Research. 34:52-58
Positron emission tomography (PET) studies have shown that cortical cerebral metabolic rate of glucose (CMRglc) is reduced in multiple sclerosis (MS). Quantitative magnetic resonance spectroscopy (MRS) measures of N-acetyl-aspartate (NAA) normalized
Autor:
Per Soelberg Sørensen, Morten Blinkenberg, Agnete Jønsson, Mads Ravnborg, Henrik Kahr Mathiesen, Jente Andresen, Lars G. Hanson
Publikováno v:
Journal of the Neurological Sciences. 245:99-102
Cognitive dysfunction in multiple sclerosis (MS) is present in approximately 50% of the patients. Only moderate correlations have been found between cognitive dysfunction and T(2) lesion load, black holes or atrophy. Cognitive dysfunction in MS is pr
Autor:
Olaf B. Paulson, Henrik Larsson, Egill Rostrup, T Tscherning, Henrik Kahr Mathiesen, Lars G. Hanson, Per Soelberg Sørensen
Publikováno v:
Magnetic Resonance in Medicine. 53:750-759
MR spectroscopy (MRS) provides information about neuronal loss or dysfunction by measuring decreases in N-acetyl aspartate (NAA), a metabolite widely believed to be a marker of neuronal viability. In multiple sclerosis (MS), whole-brain NAA (WBNAA) h
Publikováno v:
Ugeskrift for laeger. 176(3A)
The background for the use of fampridine, the indications, contraindications, side effects, and recommendations for Danish patients with multiple sclerosis are reviewed.
Publikováno v:
Ugeskrift for laeger. 174(13)
The 2010 revision of the McDonald diagnostic criteria for multiple sclerosis is reviewed. The diagnostic criteria have been simplified, which allows earlier diagnosis and treatment of multiple sclerosis.
Publikováno v:
Ugeskrift for laeger. 170(34)
The use of MRI in MS diagnosis and follow-up is reviewed. The acquirements to the MRI protocol given by the revised McDonald diagnostic criteria are discussed.